NO20032236L - Laktamforbindelse - Google Patents

Laktamforbindelse

Info

Publication number
NO20032236L
NO20032236L NO20032236A NO20032236A NO20032236L NO 20032236 L NO20032236 L NO 20032236L NO 20032236 A NO20032236 A NO 20032236A NO 20032236 A NO20032236 A NO 20032236A NO 20032236 L NO20032236 L NO 20032236L
Authority
NO
Norway
Prior art keywords
lactam compound
lactam
compound
Prior art date
Application number
NO20032236A
Other languages
English (en)
Other versions
NO324324B1 (no
NO20032236D0 (no
Inventor
James Edmund Audia
Varghese John
Lee H Latimer
Stacey Leigh Mcdaniel
Jeffrey Scott Nissen
Eugene D Thorsett
Jay S Tung
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of NO20032236D0 publication Critical patent/NO20032236D0/no
Publication of NO20032236L publication Critical patent/NO20032236L/no
Publication of NO324324B1 publication Critical patent/NO324324B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
NO20032236A 2000-11-17 2003-05-16 Laktamforbindelse samt farmasoytisk sammensetning inneholdende denne NO324324B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17
PCT/US2001/027799 WO2002047671A2 (en) 2000-11-17 2001-11-05 Lactam compound to inhibit beta-amyloid peptide release or synthesis

Publications (3)

Publication Number Publication Date
NO20032236D0 NO20032236D0 (no) 2003-05-16
NO20032236L true NO20032236L (no) 2003-07-10
NO324324B1 NO324324B1 (no) 2007-09-24

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032236A NO324324B1 (no) 2000-11-17 2003-05-16 Laktamforbindelse samt farmasoytisk sammensetning inneholdende denne

Country Status (33)

Country Link
US (1) US20050261495A1 (no)
EP (1) EP1341531B1 (no)
JP (1) JP4116437B2 (no)
KR (1) KR100819679B1 (no)
CN (1) CN1486184A (no)
AR (1) AR035927A1 (no)
AU (2) AU4319202A (no)
BR (1) BR0115427A (no)
CA (1) CA2427227C (no)
CY (1) CY1106366T1 (no)
CZ (1) CZ20031351A3 (no)
DE (1) DE60126132T2 (no)
DK (1) DK1341531T3 (no)
DZ (1) DZ3453A1 (no)
EA (1) EA005954B1 (no)
EC (1) ECSP034600A (no)
ES (1) ES2278804T3 (no)
HR (1) HRP20030383B1 (no)
HU (1) HU228117B1 (no)
IL (2) IL155960A0 (no)
MX (1) MXPA03004292A (no)
MY (1) MY134559A (no)
NO (1) NO324324B1 (no)
NZ (1) NZ525854A (no)
PE (1) PE20020802A1 (no)
PL (1) PL212199B1 (no)
PT (1) PT1341531E (no)
SI (1) SI1341531T1 (no)
SK (1) SK288065B6 (no)
TW (1) TWI305204B (no)
UA (1) UA74849C2 (no)
WO (1) WO2002047671A2 (no)
ZA (1) ZA200303789B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ES2413705T3 (es) 2005-04-08 2013-07-17 Daiichi Sankyo Company, Limited Derivado de piridilmetilsulfona
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
JP5198877B2 (ja) * 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
CA2693959A1 (en) * 2007-07-16 2009-01-22 Wyeth Inhibitors of beta amyloid production
BRPI0815135A2 (pt) 2007-08-14 2015-02-03 Lilly Co Eli Derivados de azepina como inibidores de gama secretase.
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6486272B2 (ja) 2012-09-07 2019-03-20 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞および／または支持細胞再生のための方法および組成物
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
MX2021012690A (es) 2019-04-19 2022-01-31 Ligand Pharm Inc Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
GEAP202516720A (en) 2022-09-02 2025-07-10 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
IL320396A (en) 2022-10-25 2025-06-01 Merck Sharp & Dohme Llc Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) * 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
JP2002518481A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ATE405577T1 (de) * 2000-11-17 2008-09-15 Lilly Co Eli Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung

Also Published As

Publication number Publication date
PT1341531E (pt) 2007-04-30
ECSP034600A (es) 2003-06-25
NZ525854A (en) 2004-06-25
IL155960A (en) 2009-06-15
SI1341531T1 (sl) 2007-06-30
IL155960A0 (en) 2003-12-23
PE20020802A1 (es) 2002-09-10
AU4319202A (en) 2002-06-24
HK1059731A1 (en) 2004-07-16
ZA200303789B (en) 2004-08-16
DK1341531T3 (da) 2007-05-14
KR100819679B1 (ko) 2008-04-04
HU228117B1 (en) 2012-11-28
AU2002243192B2 (en) 2006-07-20
AR035927A1 (es) 2004-07-28
SK5592003A3 (en) 2003-12-02
BR0115427A (pt) 2003-10-07
CY1106366T1 (el) 2011-10-12
EP1341531B1 (en) 2007-01-17
ES2278804T3 (es) 2007-08-16
MY134559A (en) 2007-12-31
EP1341531A2 (en) 2003-09-10
DE60126132D1 (de) 2007-03-08
TWI305204B (en) 2009-01-11
JP2004517090A (ja) 2004-06-10
CZ20031351A3 (cs) 2003-11-12
CN1486184A (zh) 2004-03-31
DZ3453A1 (fr) 2002-06-20
WO2002047671A2 (en) 2002-06-20
KR20030051846A (ko) 2003-06-25
WO2002047671A3 (en) 2003-03-06
NO324324B1 (no) 2007-09-24
HRP20030383A2 (en) 2005-10-31
US20050261495A1 (en) 2005-11-24
HUP0301842A2 (hu) 2003-09-29
CA2427227C (en) 2010-08-17
HRP20030383B1 (hr) 2007-12-31
EA200300580A1 (ru) 2003-10-30
NO20032236D0 (no) 2003-05-16
DE60126132T2 (de) 2007-10-18
JP4116437B2 (ja) 2008-07-09
SK288065B6 (sk) 2013-04-03
PL212199B1 (pl) 2012-08-31
EA005954B1 (ru) 2005-08-25
HUP0301842A3 (en) 2010-03-29
PL362688A1 (en) 2004-11-02
MXPA03004292A (es) 2004-02-12
UA74849C2 (en) 2006-02-15
CA2427227A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
NO20032236D0 (no) Laktamforbindelse
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
ATE307121T1 (de) Substituierte arylpyrazine
AR028393A1 (es) Iminoazidas substituidas
NO20032215D0 (no) Laktamforbindelse
PT1268453E (pt) Metabolitos de agonista/antagonista de estrogenio
ID29755A (id) Senyawa-senyawa organosilikon
ATE365721T1 (de) Substituierte benzoylcyclohexenone
AR028302A1 (es) Feniluracilos substituidos
IT250181Y1 (it) Custodia perfezionata per rivoltella
ATE372338T1 (de) Deshalogenverbindungen
NO20030303L (no) Kalsilytiske forbindelser
NO20031837D0 (no) Kalsilytiske forbindelser
NO20023508D0 (no) Kalsilyttiske forbindelser
TR200100070A3 (tr) Bilesim
MX231963B (es) Poliamidas
SE0003477D0 (sv) Compounds
SE0004680D0 (sv) New compound
SE0000620D0 (sv) Novel compounds
SE0003203D0 (sv) Novel compounds
SE0003979D0 (sv) Novel Compounds
SE0002331D0 (sv) Novel compounds
SE0002234D0 (sv) Novel compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees